Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584647 · ClinicalTrials.gov registry record · Phase 1
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
A Phase 1 study, sponsored by Gulam Manji.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02584647 is a Phase 1 study that was terminated before completion, run by Gulam Manji. The registered enrollment target is 39 participants.
The verdict
NCT02584647, a Phase 1 study, was terminated before completion, sponsored by Gulam Manji.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the phase I portion, the maximum tolerate dose of the study drug will be determined. In the Phase II portion, progression free survival will be assessed at the dose level found in Phase I. Participants will continue to take the study drug until they experience an unacceptable side effect or their disease progresses. Funding Source - FDA OOPD
Interventions
- DRUG sirolimus
- DRUG PLX3397
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-11-04 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584647
The ClinicalTrials.gov registry entry for NCT02584647 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gulam Manji, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sirolimus is the first listed.
NCT02584647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02584647 about?
NCT02584647 is a clinical study titled "PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors". The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the phase I portion, the maximum tolerate dose of the study drug will be determined. In the Phase II portion, progression ...
What is the current status of trial NCT02584647?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2015-11-04. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT02584647?
The interventions under investigation include: sirolimus (DRUG), PLX3397 (DRUG).
Who is sponsoring clinical trial NCT02584647?
This trial is sponsored by Gulam Manji, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.